ArticleAbdominal radiology (New York)2026
Hemorrhagic complications after ultrasound-guided percutaneous native renal biopsy: a prediction model based on clinical and ultrasonographic features under a nest case-control design.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lower eGFR is independently associated with embolization‑requiring severe bleeding after percutaneous renal biopsy: a matched case-control study with dose-respons e analysis.Renal failure · 2026Article
- Predicting Major Bleeding in Native Kidney Biopsies: From External Validation of the Universal Bleeding Score to a New Clinical Tool.Journal of clinical medicine · 2026Article
- Performing a percutaneous kidney biopsy.World journal of nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify independent risk factors for hemorrhagic complications after ultrasound-guided percutaneous native renal biopsy (UG-PRB) from clinical and ultrasonographic parameters, and to develop prediction models.
methodsThe single-center retrospective study included 2822 patients who underwent a UG-PRB between May 2022 and July 2024. Patients with post-procedural hemorrhagic complications were included as the case group. Under a nest case-control design, one procedure date-matched control without complication was randomly selected for each case. Independent predictors for overall hemorrhagic complication and severe hemorrhagic complication were investigated by multivariate logistic regression.
resultsA total of 204 patients (36.0 years ± 16.1[SD]; 104 [51%] female) developed post-biopsy hemorrhagic complications in this study. The incidence of overall and severe bleeding complications was 8.8% (204/2328) and 1.03% (24/2328), respectively. Right renal biopsy (OR 0.40, p = 0.02), number of needle passes (OR 0.40, p = 0.002), and hypertension (OR 1.29, p = 0.02) were independent risk factors for overall bleeding complications. Hyperlipidemia (OR 0.10, p = 0.04), D-dimer (OR 1.27, p = 0.03), and eGFR (OR 0.90, p = 0.002) were independent risk factors for severe hemorrhagic complications. The prediction models for overall and severe complications had AUCs of 0.64 and 0.91, and a five-cross validation in the cohort showed a mean AUC of 0.65 and 0.85 in each model. In predicting severe complications, the sensitivity and specificity were 87.5% and 75.3%, respectively.
conclusionThe developed prediction models provide effective tools for risk stratification, early prevention, monitoring, and management for patients undergoing UG-PRB.
Indexed as
Identifiers
40526135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.